Literature DB >> 22648215

Why is rosacea considered to be an inflammatory disorder? The primary role, clinical relevance, and therapeutic correlations of abnormal innate immune response in rosacea-prone skin.

James Q Del Rosso1, Richard L Gallo, Leon Kircik, Diane Thiboutot, Hilary E Baldwin, David Cohen.   

Abstract

The pathophysiology of rosacea has undergone renewed interest over the past decade, with a large body of evidence supporting the role of an abnormal innate immune response in rosacea. Many mechanisms interact with the cutaneous innate immune system that may be operative. A variety of potential triggers stimulate this immune detection system which is upregulated and hyper-responsive in facial skin of patients with rosacea as compared to normal skin. Based on the most current data, two conclusions have been reached. First, the major presentations of rosacea appear to be inflammatory dermatoses. Second, the presence of a microbial organism is not a primary or mandatory component of the pathogenesis of rosacea. Available therapies for rosacea exhibit reported modes of action that appear to correlate with the inhibition of inflammatory processes involved in the pathophysiology of at least some presentations of rosacea.

Entities:  

Mesh:

Year:  2012        PMID: 22648215

Source DB:  PubMed          Journal:  J Drugs Dermatol        ISSN: 1545-9616            Impact factor:   2.114


  10 in total

Review 1.  Kallikrein 5-mediated inflammation in rosacea: clinically relevant correlations with acute and chronic manifestations in rosacea and how individual treatments may provide therapeutic benefit.

Authors:  Aimee M Two; James Q Del Rosso
Journal:  J Clin Aesthet Dermatol       Date:  2014-01

Review 2.  The Importance of Assessing Burning and Stinging when Managing Rosacea: A Review.

Authors:  Martin Schaller; Thomas Dirschka; Sol-Britt Lonne-Rahm; Giuseppe Micali; Linda F Stein Gold; Jerry Tan; James Del Rosso
Journal:  Acta Derm Venereol       Date:  2021-10-31       Impact factor: 3.875

3.  Quality of Life in Individuals with Erythematotelangiectatic and Papulopustular Rosacea: Findings From a Web-based Survey.

Authors:  Joshua A Zeichner; Lawrence F Eichenfield; Steven R Feldman; J Scott Kasteler; Ilia L Ferrusi
Journal:  J Clin Aesthet Dermatol       Date:  2018-02-01

4.  The Burden of Illness of Erythematotelangiectatic Rosacea and Papulopustular Rosacea: Findings From a Web-based Survey.

Authors:  James Q Del Rosso; Emil A Tanghetti; Hilary E Baldwin; David A Rodriguez; Ilia L Ferrusi
Journal:  J Clin Aesthet Dermatol       Date:  2017-06-01

5.  The Role of Topical Brimonidine Tartrate Gel as a Novel Therapeutic Option for Persistent Facial Erythema Associated with Rosacea.

Authors:  Andrew William Johnson; Sandra Marchese Johnson
Journal:  Dermatol Ther (Heidelb)       Date:  2015-06-26

Review 6.  Topical Ivermectin 10 mg/g and Oral Doxycycline 40 mg Modified-Release: Current Evidence on the Complementary Use of Anti-Inflammatory Rosacea Treatments.

Authors:  Martin Steinhoff; Marc Vocanson; Johannes J Voegel; Feriel Hacini-Rachinel; Gregor Schäfer
Journal:  Adv Ther       Date:  2016-07-18       Impact factor: 3.845

7.  Topical Treatment of Rosacea with Ivermectin Inhibits Gene Expression of Cathelicidin Innate Immune Mediators, LL-37 and KLK5, in Reconstructed and Ex Vivo Skin Models.

Authors:  Séverine Thibaut de Ménonville; Carine Rosignoli; Estelle Soares; Manon Roquet; Béatrice Bertino; Jean-Paul Chappuis; Claire Defoin-Platel/Chaussade; David Piwnica
Journal:  Dermatol Ther (Heidelb)       Date:  2017-02-27

Review 8.  The role of brimonidine tartrate gel in the treatment of rosacea.

Authors:  J Mark Jackson; Melissa Knuckles; John Paul Minni; Sandra Marchese Johnson; Kevin Tate Belasco
Journal:  Clin Cosmet Investig Dermatol       Date:  2015-10-23

9.  A Tailored Approach to the Treatment of a Patient with a Severe Dynamic Manifestation of Rosacea: A Case Report.

Authors:  Martin Schaller; Lena Gonser
Journal:  Drugs R D       Date:  2016-09

Review 10.  Multidisciplinary Consideration of Potential Pathophysiologic Mechanisms of Paradoxical Erythema with Topical Brimonidine Therapy.

Authors:  James R Docherty; Martin Steinhoff; Dianne Lorton; Michael Detmar; Gregor Schäfer; Anna Holmes; Anna Di Nardo
Journal:  Adv Ther       Date:  2016-08-25       Impact factor: 3.845

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.